Belgium· BE-AMP-SAM597493-00
Oxbryta 500 mg
A voxelotor product containing voxelotor, registered in Belgium by Pfizer Europe MA. The same ATC class is registered in 8 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Voxelotor is registered in 8 of 19 countries.
Countries holding a registration under ATC B06AX03 (voxelotor), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 5 of them publish a price we can compare per daily dose
Voxelotor · ATC B06AX03
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Franceprice
- Ireland
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Voxelotor
- Manufacturer
- Pfizer Europe MA
- Country
- Belgium (BE)
- ATC code
- B06AX03
- ATC class
- Voxelotor
- Defined daily dose
- 1.5 g, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
195 interactions on record for voxelotor.
Graded by severity as the source publishes them — 45 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Voxelotor · interactions on record
195 records
- 45 severe
- 142 moderate
- 8 minor
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- DexamethasoneH02AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Voxelotor in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaOXBRYTAPfizer Europe MA EEIG, Bruxelles
- SpainOXBRYTA 500 MG COMPRIMIDOS RECUBIERTOS CON PELICULAPfizer Europe Ma Eeig
- FranceOXBRYTA 500 mg, comprimé pelliculéPFIZER EUROPE MA EEIG (BELGIQUE)
- PolandOxbrytaPfizer Europe MA EEIG
- SwedenOxbryta 500 mg Filmdragerad tablettPfizer Europe MA EEIG
- United StatesOXBRYTAGlobal Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.
- United KingdomOxbryta 500mg tabletsPfizer Ltd
- IrelandOxbrytaPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Oxbryta
- Liechtenstein · Oxbryta
- Norway · Oxbryta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/56da9aa5-9c69-425d-b889-7cb9cbf272c7 GET /v1/drugs/56da9aa5-9c69-425d-b889-7cb9cbf272c7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "SUSPENDED",
"name_en": "Oxbryta 500 mg",
"name_fr": "Oxbryta 500 mg",
"name_nl": "Oxbryta 500 mg",
"amp_code": "SAM597493-00",
"strengths": [
"500.0000",
"500.0000",
"500.0000"
],
"pack_count": 1,
"substances": [
"Voxelotor",
"Sodium Laurilsulfate"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Voxelotor",
"authorisation_numbers": [
"EU/1/21/1622/001"
]
}See everything about voxelotor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.